exagamglogene autotemcel exacel developmental name sold brand name casgevy gene therapy sickle cell disease using crispr developed vertex pharmaceuticals crispr also tested transfusiondependent therapy fda review late decision expected early approved united kingdom diseases although uncertainty risks benefits treatment institute clinical economic review estimated drugs cost effectiveness threshold million httpsenwikipediaorgwikiexagamglogeneautotemcel